Accepted Manuscript

The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma

Qi Shi, Luyan Shen, Bin Dong, Hao Fu, Xiaozheng Kang, Yongbo Yang, Liang Dai, Wanpu Yan, Hongchao Xiong, Zhen Liang, Keneng Chen

PII: S0304-3835(18)30408-7

DOI: 10.1016/j.canlet.2018.06.010

Reference: CAN 13943

To appear in: Cancer Letters

Received Date: 24 February 2018

Revised Date: 12 May 2018

Accepted Date: 6 June 2018

Please cite this article as: Q. Shi, L. Shen, B. Dong, H. Fu, X. Kang, Y. Yang, L. Dai, W. Yan, H. Xiong, Z. Liang, K. Chen, The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.06.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Abstract

The activation of ATM (ataxia-telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related), is essential for DNA damage repair and the maintenance of genomic stability. Therefore, ATM or ATR inhibition is considered as a promising strategy for sensitizing cancer cells to chemotherapy. This study is aimed to explore the effect of ATR inhibitor on sensitizing ESCC (esophageal squamous cell carcinoma) cells to cisplatin, and whether ATM deficiency could impact the sensitization. We found that 21.5% of ESCC cases had ATM deficiency and that patients with ATR activation after neoadjuvant chemotherapy had worse chemotherapy response and poorer overall survival than that without ATR activation (32 mons vs. >140mons). Then, it was shown that VE-822 inhibited CHK1 activation, leading to the accumulation of cisplatin-modified DNA. And it inhibited cell proliferation, induced cell cycle arrest in G1 phase and enhanced cell apoptosis. Moreover, VE-822 significantly sensitized ESCC cells to cisplatin, and these two drugs had synergistic effects, especially in ATM-deficient cells, in vitro and in vivo. Our results suggest that ATR inhibition combining with cisplatin is a new strategy for managing patients with ESCC, especially patients with ATM-deficiency.

1	The identification of the ATR inhibitor VE-822 as a therapeutic strategy				
2	for enhancing cisplatin chemosensitivity in esophageal squamous cell				
3	carcinoma				
4	Running title: ATR inhibitor sensitized ESCC cells to chemotherapy				
5					
6	Qi Shi ^{1*} , Luyan Shen ^{1*} , Bin Dong ² , Hao Fu ¹ , Xiaozheng Kang ¹ , Yongbo Yang ¹ ,				
7	Liang Dai ¹ , Wanpu Yan ¹ , Hongchao Xiong ¹ , Zhen Liang ¹ , Keneng Chen ¹ .				
8	Key Laboratory of Carcinogenesis and Translational Research (Ministry of				
9	Education), 1Department of Thoracic Surgery I, 2Department of Pathology,				
10	Peking University Cancer Hospital & Institute, Beijing, People's Republic of				
11	China				
12	*Qi Shi and Luyan Shen contributed equally to this work				
13	Corresponding author: Keneng Chen, Department of Thoracic Surgery I, Key				
14	Laboratory of Carcinogenesis and Translational Research (Ministry of				
15	Education), Peking University Cancer Hospital & Institute, No. 52, Fucheng Rd,				
16	Haidian Dist, Beijing 100142, P.R. China. Phone: 86-10-88196536; Fax:				
17	86-10-88196526; E-mail: chenkeneng@bjmu.edu.cn.				
18					
19					

20 Abstract

21 Inducing DNA damage is known to be one of the mechanisms of cytotoxic 22 chemotherapy agents for cancer such as cisplatin. The endogenous DNA 23damage response confers chemoresistance to these agents by repairing DNA 24 damage. The initiation and transduction of the DNA damage response (DDR) 25 signaling pathway, which is dependent on the activation of ATM 26 (ataxia-telangiectasia mutated) and ATR (ataxia telangiectasia and 27Rad3-related), is essential for DNA damage repair, the maintenance of 28 genomic stability and cell survival. Therefore, ATM or ATR inhibition is 29 considered as a promising strategy for sensitizing cancer cells to 30 chemotherapy. This study is aimed to explore the effect of ATR inhibitor on 31 sensitizing ESCC (esophageal squamous cell carcinoma) cells to cisplatin, 32 and whether ATM deficiency could impact the sensitization. We found that 33 21.5% of ESCC cases had ATM deficiency and that patients with ATR 34 activation after neoadjuvant chemotherapy had worse chemotherapy response 35 and poorer overall survival than that without ATR activation (32 mons 36 vs. >140mons). Then, it was shown that VE-822 inhibited ATR-CHK1 pathway 37 activation, leading to the accumulation of cisplatin-modified DNA. And it 38 inhibited cell proliferation, induced cell cycle arrest in G1 phase and enhanced 39 cell apoptosis. Moreover, VE-822 significantly sensitized ESCC cells to 40 cisplatin, and these two drugs had synergistic effects, especially in 41 ATM-deficient cells, in vitro and in vivo. Our results suggest that ATR inhibition 42 combining with cisplatin is a new strategy for managing patients with ESCC, 43 especially those with ATM-deficiency. However, this is an idea that requires 44 further validation.

45

46 **Highlights**:

47 ● ATR activation was associated with efficacy of neoadjuvant

48 chemotherapy.

49 • VE-822 promoted cell apoptosis and induced cell cycle arrest in ESCC
 50 cells.

• VE-822 sensitized ESCC cells to cisplatin, in vitro and in vivo.

- VE-822 along with cisplatin induces DNA-cisplatin adduct accumulation.
- 53

54 Key words: DNA damage response; chemoresistance; ATM deficiency; ATR
 55 inhibitor

56

57 **1. Introduction**

Esophageal carcinoma (EC) is the 8th most common cancer worldwide[1]. 58 EC ranks as the 6th most common cause of cancer-related morbidity and the 59 4th most common cause of cancer-related mortality in China[2]. EC comprises 60 61 the following two major pathological types: adenocarcinoma and squamous 62 cell carcinoma. The majority of ESCC cases occur in Asia, particularly in north 63 China. Surgery is known as the main treatment for ESCC, but long-term 64 survival of patients with advanced disease remains poor and unsatisfactory. Currently, the development of comprehensive perioperative therapies has 65 66 greatly improved the efficacy of ESCC treatment, especially for long-term 67 survival. Platinum-based combination regimen is used most frequently in the 68 clinical practice; however, previous studies have demonstrated that the 69 improved efficacy associated with neoadjuvant therapy is limited to patients 70 who respond to chemotherapy, and the prognosis of non-responders is worse 71compared with that of patients who received surgery alone[3, 4], probably because of chemotherapy resistance, which is inevitable. Thus, new 72 73 approaches to conquering chemoresistance to improve chemotherapy 74effectiveness are urgently needed.

75 Platinum-based drugs cross-link with double-stranded DNA and form 76 DNA-platinum abduct to induce DNA damage, leading to cell apoptosis[5]. Due to the intrinsic DDR mechanism, the DNA damage could be repaired. DDR 77 78 initiation relies on the activation of two major kinase systems, namely, 79 ATR/CHK1 and ATM/CHK2 pathways. Sequentially activated ATR and ATM 80 directly phosphorylate the kinases CHK1 and CHK2, respectively, to activate 81 the downstream effectors such as p53 to upregulate cell cycle checkpoint 82 pathways and then repair the DNA damage[6]. Therefore, DDR is an important 83 chemoresistance mechanism through which tumor cells escape from DNA 84 damage induced by genotoxic agents and thus avoid cell death[7-10]. It has 85 been reported that many malignant cancers are characterized by the functional 86 loss or deficiencies in key proteins involved in the DDR, most notably ATM and 87 p53[5, 6, 11-14]. ATM or p53 deficiency in cells leads to synthetic lethality in 88 the presence of ATR depletion[15-19]. Therefore, ATR blockades are 89 considered as promising therapeutic targets, as ATR inhibition may have 90 deleterious effects on cancer cells.

91 Previous studies have demonstrated ATR inhibition is effective for treating 92 cancers combining with chemotherapies in lung adenocarcinoma, gastric 93 cancer, HER2 positive breast cancer and chronic lymphocytic leukemia cells to 94 enhance chemotherapy sensitivity[16-18, 20-22]. VE-822 is an orally, highly 95 specific ATR inhibitor, which has been entered clinical trials. However, we 96 have less knowledge about not only the effect of ATR inhibition in ESCC, but 97 also whether it enhance the chemotherapy sensitivity.

In this study, we firstly examined ATM expression status in ESCC and analyzed the association between ATR activation with chemotherapy response evaluated with TRG and overall survival of patients who underwent neoadjuvant chemotherapy. Then, we investigated the effect of VE-822 or combination with cisplatin in ESCC in vitro and in vivo with the context of

endogenous ATM activation or ATM deficiency by CRISPR. It was
demonstrated that VE-822 could block the activation of ATR, which
consequently increase DNA damage and sensitize tumor cells to
chemotherapy, with presenting the synthetic lethality effect, especially when
ATM was deficient.

108

109 **2. Materials and methods**

110 2.1 Patients

All data of the patients included in this study were retrieved form our 111 112 prospective database for esophageal cancer, which is established beginning in 113 January 2000 at the Department of Thoracic Surgery, Peking University 114 Cancer Hospital (Beijing, China). From January 2000 to December 2012, 954 115cases of esophageal cancer underwent surgery, of which, 651 cases were 116 diagnosed as ESCC. According to strict entry criteria, 144 patients who underwent esophagectomy followed by adjuvant chemotherapy and 110 117 118 who underwent neoadjuvant chemotherapy followed patients by 119 esophagectomy were enrolled in this study. The detailed clinicopathological 120 characteristic of patients were listed in supplementary information. The study 121 was approved by the Ethics and the Academic Committees of Peking 122 University Cancer Hospital (Beijing, China) and informed verbal consent was 123 obtained from all patients.

- 124
- 125 **2.2** Chemotherapy and surgery methods

126 One hundred and forty-four patients underwent esophagectomy first. After 127 4-6 weeks, they were treated with adjuvant chemotherapy including 128 platinum-based double drug regimen, mainly of which are the paclitaxel and 129 cisplatin at the proportion of 95%. One hundred and ten patients were treated 130 by neoadjuvant chemotherapy including platinum-based double drug

combination, mainly the paclitaxel and cisplatin with the proportion of 95%. 131 132 The curative effects of the treatment were evaluated by enhanced chest 133computed tomography (CT) and esophagography. Approximately 1-4 cycles of 134 neoadjuvant chemotherapy were administered before surgery. Surgery was 135carried out 3-5 wk. after neoadjuvant chemotherapy. Chemotherapy regimen was as follows: On day 1, paclitaxel at a dose of 175 mg/m² of body surface 136 area was administered intravenously. On day 1-3, cisplatin at a dose of 25 137 mg/m² of body surface area was administered intravenously, a single course of 138 139 treatment lasted 21 days.

140

141 2.3 Tumor regression grade assessment (TRG)

H&E staining results of all the enrolled subjects were reviewed by two experienced pathologists who were blinded to the clinical information and associated issues. Tumors were graded by TRG which was a four-point scale based on the histological tumor response assessment[23]. This assessment was described as: grade I, no residual tumor cells; grade II, nearly complete response with <10% vital residual tumor cells (VRTCs); grade III, 10-50% VRTCs; and grade IV, >50% VRTCs.

149

150 **2.4 Follow-up**

Follow-up evaluation consisted of outpatient interviews at 3-month intervals for 2 years, then at 6-month intervals for 3 years, and finally at 12-month intervals until death. Outpatient follow-up visits included recording of symptoms and findings of body examinations such as CT, upper esophagography, ultrasound, and gastroscopy, if necessary. After 2010, some subjects underwent positron emission tomography-computed tomography (PET-CT) examinations. Overall survival (OS) was measured from surgery

date until death or the last follow-up. The latest follow-up was June 1st, 2017
at the rate of 93%.

160

161 2.5 Immunohistochemistry (IHC)

162 Specimens of the included patients were retrieved from department of 163 pathology, Peking University Cancer Hospital. After routine deparaffinization 164 and hydration, tissue sections were treated with 3% hydrogen peroxide and 165 then heated in citrate solution for antigen retrieval. After antigen retrieval, the sections were incubated with 10% normal goat serum to block any nonspecific 166 167 reaction. Then, the sections were incubated with rabbit monoclonal anti-ATR (phospho S428) antibody (Abcam, ab178407, at 1:500) or mouse monoclonal 168 169 anti-ATM antibody (Abcam, ab78, at 1:1000) overnight at 4°C. Dako REAL EnVision Detection System, Peroxisase/DAB, Rabbit/Mouse (K5007), was 170 171used as the secondary antibody and for staining. The immunohistochemical 172signals were scored by two independent pathologists. To evaluate ATR-pS428 and ATM expressions, immunohistochemical staining was classified into the 173174following four groups according to intensity. The staining intensity was 175categorized by relative intensity as follows: 0, negative; 1, weak; 2, moderate; 176 and 3, strong.

177

178 2.6 Cell lines and cell culture

Human ESCC cell lines KYSE450, KYSE150, KYSE70, KYSE180, and KYSE 510 were purchased from the Japanese Collection of Research Biosources cell bank (Osaka, Japan). Identities of the cell lines were confirmed by standard STR analysis matched with the American Tissue Culture Collection (ATCC) and Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). All cells were passaged for less than 1 year before use and cultured in RPMI-1640 medium (Hyclone; GE Healthcare,

Logan, UT, USA) with 10% heat-inactivated fetal bovine serum and 1%
penicillin-streptomycin solution at 37°C in a humidified atmosphere containing
5% CO₂. ATM-deficient ESCC cells were established in KYSE450, KYSE70,
KYSE180 and KYSE150 by CRISPR.

190

191 2.7 CRISPR/cas9 plasmids and virus infection

Establishment of ATM-deficient ESCC cells by lenti-CRISPR/CAS9 vectors was associated with the following sequences: GTTTCAGGATCTCG AATCAGG/CAAGGAAAATATTTGAATTGG. 5×10^6 cells were seeded in a 10cm dish overnight at 37°C and virus in the presence of polybrene (8µg/ml, Sigma, Japan) were added to KYSE cell lines. For selection, using puromycin (2µg/ml, Beyotime Biotechnology, China) to treat cells for 3 weeks to eliminate uninfected cells.

199 We used PCR and DNA-seq for validation of ATM knockdown. Total DNA 200 from KYSE70, KYSE450 and their ATM knockout cells was extracted with 201 TIANamp Genomic DNA Kit (TIANGEN, DP304; China). The sequences of the 202 PCR primers were as follows: ATM forward, 5'- CTGCTTATCTGCTGCCGT-3' 203 5'-GTTTGCCACTCCTGTCC-3': and reverse. GAPDH forward, 204 5'-GTTTGCCACTCCTGTCC-3'; and reverse, 5'-GGCATGGACTGTGGTCA 205 TGAG-3'. Then, we authorized Microread Gene Company (Beijing, China) for 206 DNA-seq.

- 207
- 208 2.8 Regents

Cisplatin and ATR inhibitor VE-822 were purchased form Sigma (479306)
and Selleck (S7102), respectively. Cisplatin were dissolved in normal saline as
1 mg/ml and VE-822 was dissolved in DMSO as 10mM.

212

213 **2.9** Cisplatin modified DNA accumulation test

214 Cisplatin modified DNA accumulation was examined using flow cytometry 215 (BD, Biosciences) by anti-cisplatin modified DNA antibody (Abcam, ab103261). 216 Cells in culture were treated with cisplatin, VE-822, or combination of these 217two drugs, with un-treated cells as control. Cells were fixed with 70% ehtanol 218 for 30 min at 4°C and permeabilized with 0.3% TritonX-100 in PBS. The cells 219 were incubated with the primary antibody (1:200) for 18 hours at 4°C. A rabbit 220 anti-rat IgG/Alexa Fluor 488 (Bioss, 1/100) was used as the secondary 221 antibody. An isotype control used Rat IgG2a kappa monoclonal (Abcam, 222 ab18450), simultaneously,

223

224 2.10 Western blotting

225 The proteins were extracted by using RIPA lysis buffer and separated by 226 10% SDS-PAGE with 30µg protein per lane and transferred onto a 227 polyvinylidene uoride membrane, followed by western blot analysis. The 228 membrane was blocked using 5% bovine serum albinum at room temperature 229 for 1 h. It was then immunoreacted with, ATM, p-ATM (S1981), ATR, p-ATR 230 (Ser428), Chk1, p-Chk1, Chk2, p-Chk2, p53, p21, p-STAT3, STAT3, p-AKT, 231 AKT, caspase-3, p-histone H2A.X and PARP were acquired from Cell 232 Signaling Technology(America). GAPDH (ZSGB-BIO, China) were also 233 purchased. Goat anti-rabbit or anti-mouse polyclonal IgG was used as a 234 secondary antibody.

235

236 2.11 Cell proliferation assay (CCK-8 assay)

Five thousand cells per well were plated in 96-well plates overnight at 37°C and treated with gradient dilution of cisplatin (0.125, 0.25, 0.5, 1, 2, 4, 8, 16 and 32 μ g/ml) or VE-822 (0.125, 0.25, 0.5, 1, 2, 4, 8, 16 and 32 μ M), or combination of cisplatin (0.125, 0.25, 0.5, 1, 2, 4, 8, 16 and 32 μ g/ml) and VE-822 (2 μ M). After 48h of incubation, 10 μ l CCK-8 reagent (Dojindo

Molecular Technologies Inc., Kumamoto, Japan) was added to each well about 2h at 37°C. Then, the absorbance of each well was examined at 450 nm by the Microplate reader (iMark, Bio-rad, USA).

245

246 2.12 Cell cycle analysis

Cells at a density of 1*10⁶ per well were plated in 6-well plates overnight at 247 37°C and treated with cisplatin, or VE-822 or combination for 24h until cells 248 were harvested. Cells at a density of $1*10^6$ were collected and fixed with 70% 249 cold ethanol overnight at 4°C. After fixation, cells were washed 3 times in PBS. 250 251Then, the PI-staining solution with RNase A (BD Biosciences) was added 252about 30 min in room temperature to stain samples and were run on the 253FACScan cytometry (BD Biosciences, America), and data were analyzed 254using FlowJo software (Tree Star).

255

256 2.13 Apoptosis analysis in vitro

Cells at a density of 1*10⁶ per well were plated in 6-well plates overnight at 257 25837°C and treated with cisplatin, or VE-822 or combination for 8h until cells were harvested. Cells were washed 3 times in PBS and incubated in trypsin 259 260 (without EDTA) at 37°C for 10min. Cells were rinsed 3 times in PBS and re-suspended in binding buffer (Dojindo, Japan). Annexin V-FITC antibody 261 (Dojindo, Japan, 5 µl) and PI (Dojindo, Japan, 5 µl) were added in cells (1 × 262 10⁵ cells/100µl) and incubated for 15 min at room temperature in the dark. 263 Then, the samples were analyzed by flow cytometry (BD Biosciences, America) 264 within 1 h. 265

266

267 2.14 Immunofluorescence (y-H2AX and p53 foci formation)

268 Before the assay, the cells treated with 2µg/ml cisplatin, 2µM VE-822 and 269 the combination of these two drugs for 24h. The coverslips were rinsed 3 times

270 in PBS, fixed in 3.7% paraformaldehyde for 15min, permeabilized with PBST 271 (0.5% Triton X-100 in PBS) for 5min and blocked specimen in blocking buffer 272 (5% normal serum in PBST) for 60min at room temperature. After washing 3 273times in PBS, the coverslips were incubated with phospho-Histone H2A.X 274 (Ser139) primary antibody (#9718, Cell Signaling Technology; America) at a 275dilution of 1:200 and p53 primary antibody at a dilution of 1:2000 (#2524, Cell 276 Signaling Technology; America) overnight at 4°C. Then, the coverslips were 277washed times PBS and incubated with the appropriate 3 in TRITC 278 fluorophore-conjugated secondarv antibodv: for v-H2A.X 279 (tetramethylrhodamine goat anti-rabbit IgG, Invitrogen, American) and FITC for 280 p53 (fluorescein goat-mouse IgG, Invitrogen, American) for 1h at room 281 temperature in the dark. Finally, the cells were counterstained with DAPI (300 282 nmol/I; Invitrogen, American). Immunofluorescence was visualized by Zeiss 283 scanning microscope(Germany).

284

285 2.15 RNA-seq library construction and sequencing

286 Total RNA from KYSE450 and KYSE450 treated with cisplatin (1µg/ml) and VE-822(1µM) (named KYSE450.1) with three replications was isolated 287 288 using Trizol for the construction of a RNA-seg library and sequencing. The construction of RNA-seq library was performed using the KAPA Stranded 289 mRNA-Seq Kit (Illumina[®] platform) (product codes KK8420 and KK8421, 290 291 Boston, Massachusetts, United States) following the manufacturer's 292 instructions. Briefly, mRNA was extracted and purified from total RNA ,then 293 fragmented and primed for cDNA synthesis. Double-stranded cDNAs were 294 synthesized and then purified with 1.8x Agencourt AMPure XP beads (Beckman Coulter, Beverly, USA) followed by the end 2nd Strand Synthesis. 295 296 After A-Tailing, Illumina adapter oligonucleotides were ligated to cDNA fragments, and the 1X SPRI[®] cleanup was performed. Suitable cDNA 297

298 fragments were selected as templates for PCR amplification using the KAPA 299 Library Amplification Primer Mix and KAPA HiFi Hot Start Ready Mix. Products 300 were purified with the AMPure XP bead system and quantified using a 301 Bioanalyzer (Agilent high sensitivity chip). Finally, RNA-seq libraries were 302 sequenced using an Illumina HiSeg at Beijing Microread Genetics Co Ltd 303 (Beijing, China). Raw data were processed with Fastp using recommended 304 parameters. The filtered reads were mapped to Hg19 by hista2. The bam files 305 were processed with samtools. Feature Counts was used to calculate gene 306 expression. A list of differential expression genes (DEGs) was identified using 307 the R packages" EdgeR". P-value of 0.05 and |log2(foldchange)|>2 were set 308 as the threshold for significantly differential expression by default. Gene 309 Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) 310 enrichment analysis of differentially expressed genes were implemented with 311 KOBAS3.0. GO classification was done by the R packages "TopGO".To 312 further validate the RNAseq results, we selected 10 DEGs of our interests to 313 examine their expression in both samples by using qRT-PCR. The 314 gene-specific primers for these twenty genes are listed in Table S1.

- 315
- 316 2.16 Primary ESCC xenograft models

317 BALB/c nude mice were raised under the care of the Laboratory Animal 318 Unit of First Affiliated Hospital of PLA General Hospital, China. KYSE70, KYSE70 ATM (-), KYSE450, and KYSE450 ATM (-) (3 × 10⁶) cells suspending 319 in 200 µI PBS were injected into the right groin of 8 weeks old female Balb/C 320 321 nude mice. All mice were housed and raised under specific pathogen-free 322 conditions. The sizes of tumors and body weight of each mouse were 323 measured every 3 days. Tumor volumes were calculated using the following 324 formula: tumor volume = $[(length) \times (width) \times (width)] / 2$. When the tumor volume reached about 200 mm³, the mice were divided into two groups 325

326 randomly (6 mice per group). First group of mice were given 5mg/kg cisplatin 327 on days1, 4, 7, 10 via intravenous injection. The second group were given 60 328 mg/kg VE-822 on days 1, 3, 5 via oral gavage. The third group were given both 329 of cisplatin and VE-822, the last group were given PBS as control. At the end 330 of the measurement period, excised tumors were measured by a slide caliper 331 for volume and weighted by an electronic analytical balance. All experiments 332 were done in accordance with institutional standard guidelines of Peking 333 University Cancer Hospital and Unit of First Affiliated Hospital of PLA General 334 Hospital for animal experiments.

335

336 2.17 Statistical analysis

337 SPSS software (version 24.0; IBM SPSS, Armonk, NY, USA) was used to 338 perform the statistical analysis. The relationships between ATR-pSer428 and 339 ATM expression and clinicopathologic characteristics were tested using 340 Chi-square test. Survival curves were plotted by Kaplan-Meier method and 341 compared by log rank test. The association between gene expression and TRG were evaluated using a γ^2 test. All in vitro experiments were performed at 342 343 least 3 times with triplicates. Comparisons between groups for statistical 344 significance were performed with a 2-tailed unpaired Student's t test. Bars and 345 error bars on the graphs as well as data in the text represent the mean \pm SD. P 346 < 0.05 was considered statistically significant.

347

348 **3. Results**

349 **3.1 ATM protein was deficient in 21.5% ESCC patients**

Many studies have reported that various tumors had ATM deficiency with different degrees. Therefore, we examined the expression rate of ATM through IHC in 144 ESCC patients' samples without preoperative treatment(Fig 1a). The result showed that 21.5%(31/144) of cases were ATM expression

negative. ATM expression was not associated with the clinicopathologic
factors such as age, gender, pathologic stage and tumor location as well as
overall survival (Fig S1, Table S2).

357

358 3.2 ATR activation was associated with efficacy of neoadjuvant 359 chemotherapy

360 ATR-pSer428 is the active form of ATR protein. ATR-pSer428 expression 361 was examined in a cohort of 110 ESCC patients underwent neoadjuvant 362 chemotherapy. Then, we evaluated the relationship between the activation of 363 ATR (substituted by the expression of ATR-pSer428) in resected specimens and overall survival or TRG. The expression of ATR-pSer428 in ESCC mainly 364 365 occur in nucleus. Among the 110 subjects in the study, 25.5% (28/110) cases 366 ATR-pSer428 negative. whereas 74.5%(82/110) were cases were 367 ATR-pSer428 positive. Then, we divided the patients with ATR-pSer428 368 expression into subgroups according to ATR-pSer428 expression intensity, which was graded 0, 1, 2, or 3 (Fig 1b). We found that 25.5% (28/110), 17.3% 369 370 (19/110), 32.7% (26/110), and 24.5% (27/110) of patients displayed grade 0, 1, 371 2 and 3, respectively. Kaplan-Meier analysis of the 110 subjects showed that 372 more than half of the subjects without ATR-pSer428 expression survived until the follow-up endpoint (144 months), whereas the median survival time for 373 374 ESCC patients with ATR-pSer428 expression was only 32 months (P < 0.05). 375 The median survival time of patients with grade 1, 2, and 3 were 38, 28 and 28 376 months, respectively. More than half of the subjects with grade 0 expression 377 survived until the follow-up endpoint (144 months) (P < 0.05) (Table 1, Fig 1c). 378 We further defined grades 0 and 1 as low-level expression and grades 2 and 3 as high-level expression. Thus, 42.7% (47/110) of patients had low-level 379 expression of ATR-pSer428, and 57.2% (63/110) of patients had high-level 380 381 expression of ATR-pSer428. Half of the patients with low-level expression of

ATR-pSer428 survived until the follow-up endpoint (144 months). The median
survival time of the patients with high-level expression of ATR-pSer428 was 28
months (P < 0.05) (Table 1, Fig 1c).

385 TRGs is currently the standard pathological indicators of neoadjuvant chemotherapy responsiveness. In this study, we found that ATR-pSer428 386 387 expression was significantly associated with TRGs. ATR-pSer428 expression 388 in subjects with TRGs 2/3/4 was higher than that in subjects with TRGs 1 (P < 389 0.001) (Table 2). That is, patients with ATR activation after chemotherapy 390 display an unfavorable response to chemotherapy compared with those 391 without ATR activation, indicating that ATR-pSer428 expression can be used 392 to determine chemotherapy sensitivity.

393

394 3.3 DDR signaling pathway was activated in ESCC cell lines and was 395 inhibited by VE-822, which also inhibited cell proliferation

396 To assess the baseline of ATM/ATR signaling pathway activation, we performed western blotting to examine the expression of phosphorylated ATM, 397 398 ATR, CHK1, and CHK2, which serve as surrogate markers for ATR and ATM pathway activation, and the expression of the downstream target p53 in 399 400 KYSE70, KYSE150, KYSE180, KYSE450, and KYSE510 cell lines. The results showed that p-ATM, p-ATR, p-CHK1, p-CHK2 and p53 were 401 402 endogenously activated in all ESCC cell lines (Fig 2a and Fig S2). Based on 403 these results, we inferred that ATM/ATR signaling pathway activation is essential for overcoming replication stress and sustaining tumor cell genomic 404 stability. In these five cell lines, the baseline ATR activation was stronger in 405 406 KYSE450 and KYSE70 than other cell lines. Then, we used CCK-8 assay to 407 investigate the effect of VE-822 on cell viability. Forty-eight hours of treatment with VE-822 robustly inhibited ESCC cell viability. The half maximal inhibitory 408 409 concentration (IC50) were 3.982, 11.870, 2.606, 6.922 and 9.387 in KYSE450,

410 KYSE150, KYSE510, KYSE180 and KYSE70 cells, respectively (Fig 2b). We 411 chose two ESCC cell lines, namely, KYSE70 and KYSE450, for the ATR 412 inhibition experiments. We found that p-ATR and p-CHK1 activation was 413 significantly inhibited by the ATR inhibitor VE-822. We also found that DNA 414 damage remarkably accumulated and y-H2AX fluorescence intensity amplified. 415 as detected by Western Blotting (Fig 2c). In addition, VE-822 at least partially 416 inhibited cancer cell proliferation through Stat-Akt signaling pathway inhibition 417 (Fig 2d).

418

419 3.4 VE-822 promoted cell apoptosis and induced cell cycle arrest in 420 ESCC cells

421 ATR activation is a key step in DDR initiation, as ATR-pSer428 induces 422 activation of DNA damage checkpoint signaling, which induces cell cycle 423 arrest. ATR plays an important role in the G2-M phase transition. Consistent 424 with this finding, we found that the cell cycle was arrested in G1 phase in a 425 concentration-dependent manner after the cells being exposed to increasing 426 concentrations of VE-822 (1.0 µM, 2.0 µM, and 4.0 µM) for 24 h. As Fig 2e 427 shown, VE-822 increased the fraction of cells in G1 phase to 68.48% 428 (compared with baseline 52.62%) in KYSE70 cells and 42.22% (compared 429 with baseline 37.48%) in KYSE450 cells when administered at a dose of 4.0 430 µM. VE-822-induced cell cycle arrest also led to the downregulation of p21 431 expression (Fig 2f).

To determine the effect of VE-822 on cell apoptosis, we examined the ratio of apoptotic cells to live cells using flow cytometry. VE-822 induced a significant concentration-dependent increase in cell apoptosis in both KYSE70 and KYSE450 cells after 8 h of treatment (Fig 2g). We also examined the expression of caspase-3, cleaved PARP by western blotting, as the indicated

proteins are biomarkers for cell apoptosis. The results showed that caspase-3
and cleaved PARP expression was increased by exposure to VE-822 (Fig 2g).

440 3.5 VE-822 sensitized ESCC cells, especially ATM-deficient cells, to 441 cisplatin in vitro and in vivo

442 Cisplatin is commonly used as a first-line chemotherapy for patients with 443 ESCC. However, chemoresistance inevitably occurs spontaneously or 444 develops during treatment. Previous studies have demonstrated that ATR kinase inhibitors could enhance the sensitivity of cancer cells to DNA 445 446 damaging agents, such as cisplatin, in solid-tumor models both in vitro and in 447 vivo. To validate the hypothesis that ATR inhibition enhances the efficacy of 448 cisplatin in ESCC, we performed CCK-8 assay to evaluate the viability of cells 449 exposed to cisplatin, VE-822 or the combination of cisplatin and VE-822 and to 450 determine the effect of these treatments on tumor growth in ESCC mouse 451 xenograft models. The combination of ATR inhibition and cisplatin synergistically inhibited cell viability in KYSE 450 and KYSE70 cells. The 452 453combination index(CI) values were calculated according the to Chou-Talalay[24] median-effect principle. As shown in the figure 3a, there is 454 significant synergistic effect between VE-822 and cisplatin. Then, to 455 456 investigate whether ATM deficiency affect the efficacy of VE-822, we knockout 457 ATM expression by using CRISPR and established stable cell strain by 458 screening (Fig 3b). And we found that IC50 of VE-822 was decreased 459 significantly in ATM (-) cells (Fig 3c) and more striking synergistic inhibition combination treatment was observed in ATM-deficient cells than in cells 460 461 expressing ATM (Fig 3d). Then, we treated the mouse xenograft models with 462 cisplatin (5 mg/kg) on days 1, 3, and 5; VE-822 (60 mg/kg) on days 1, 2, and 3; 463 or combination therapy, with PBS as control. The growth of tumors treated with 464 combination therapy was significantly slower than that of tumors treated with

465 cisplatin or VE-822 alone. On day 14, the TGI of KYSE70 xenograft tumor 466 were 28.8% 25.9% and 73.3% for cisplatin-alone group, VE-822-alone group and combination group respectively. And on day 16, the TGI of KYSE450 467 468 xenograft tumor were 58.7%, 30.6% and 83.2%, respectively. However, the TGI of ATM-deficient KYSE450 xenograft tumor were 38.0%, 48.1% and 85.2% 469 470 respectively (Fig 3e). The result indicated that ATM-deficiency magnified the 471effect of VE-822 in KYSE450 cell line. However, body weight loss in mice 472 treated with combination therapy was not significantly greater than that in mice treated with monotherapy (Fig 3f). Furthermore, p-CHK1, p-AKT activation 473 474 was inhibited, and cleaved-PARP expression was increased as detected by Western Blotting (Fig 3g). The accumulation of cells in S phase was greater in 475 476 ATM-deficient KYSE450 and KYSE70 cells than control cells treated with 477 VE-822 (Fig 4a). VE-822 reinforced the effects of cisplatin to induce cell 478 apoptosis, especially for ATM-deficient cells. As Fig 4b shown, the 479combination of VE-822 and cisplatin caused a significant increase in cell apoptosis in both ATM-deficient KYSE450 and KYSE70 cells compared with 480 481 control cells. Accordingly, caspase-3 and cleaved-PARP expression remarkably increased (Fig 4c). Then, we observed that VE-822 induced 482 483 accumulated DNA damage and amplified y-H2AX and p53 fluorescence 484 intensity in wild-type cells (Figure 5a and 5b) and ATM-deficiency cells (Fig 5c 485 and 5d). These results suggested that the combination of VE-822 and cisplatin 486 has therapeutic potential, especially in ATM-deficiency cells.

487

488 3.6 ATR inhibition along with cisplatin induces DNA-cisplatin adduct 489 accumulation, especially in ATM (-) ESCC cells

490 Cisplatin cross-links with DNA to form cisplatin-DNA adducts, causing cells
491 to experience replication stress and undergo apoptosis; however, cells have
492 an endogenous repair mechanism, known as the DDR, to conquer this type of

493 stress. Inhibitors targeting the DDR can theoretically block the DDR and 494 enhance cisplatin-DNA adduct formation. To explore the mechanism by which VE-822 sensitizes ESCC cells to cisplatin, we used an anti-cisplatin-modified 495 496 DNA antibody to detect cisplatin-modified DNA accumulation in cells treated 497 with cisplatin, VE-822 or the combination of the two drugs. The results showed 498 that VE-822 combined with cisplatin induced greater accumulation of modified 499DNA than either agent alone, especially in ATM-deficient ESCC cells (Figure 500 6). In conclusion, VE-822 sensitized ESCC cells to cisplatin by increasing the 501 DNA damage induced by cisplatin and inducing the enrichment of cisplatin in 502 cells.

503

504 **4. Discussion**

505 Chemoresistance to platinum-based chemotherapy has been a huge 506 challenge with respect to achieving optimal treatment outcomes in ESCC. 507 DNA damage induced by cisplatin-DNA adducts causes DNA replication 508 stress and triggers the DDR, which is considered an important mechanism for 509 the development of chemoresistance [6]. Previous studies have shown that 510 DNA replication stress induced by genotoxic agents, such as cisplatin, allows 511 inhibitors targeting the DDR pathway to serve as an effective therapy for 512 ESCC. ATM and ATR inhibitors have been entered into clinical trials pertaining 513to some types of solid cancers. However, whether DDR inhibitors can be used 514 in ESCC treatment is not known. In our study, we found that endogenous DNA 515 replication stress occurs in ESCC cells. p-ATM and p-ATR were endogenously 516 expressed in ESCC cells, and their activation was significantly enhanced upon 517exposure to cisplatin. This finding serves as an important clue indicating that 518 DDR pathway inhibitors can be used in ESCC treatment.

519 Interestingly, we found that ATR activation (represented by ATR-pSer428 520 expression) was associated with a pathologic response to chemotherapy and

521 poorer long-term outcomes in patients who underwent neoadjuvant 522 chemotherapy, indicating that p-ATR expression may be used as a biomarker 523 for chemoresistance in ESCC. Therefore, we hypothesized that the 524 combination of ATR inhibition and platinum is an effective therapy for ESCC, 525 which relies on ATR signaling to facilitate DNA repair. We found that ESCC 526 cells were sensitized to cisplatin upon exposure to an ATR inhibitor in vitro and 527 in vivo, a finding supported by the data pertaining to cell viability. Additionally, 528 we demonstrated that STAT3 may play a critical role in VE-822-mediated 529 effects, as p-STAT3 expression was remarkably inhibited in KYSE450 and 530 KYSE70 cells treated with the combination of cisplatin and VE-822. In previous study, it has been shown that STAT3 was essential for efficient repair of 531532 damaged DNA, which was suppressed when DNA damage response was 533 inhibited[25-27]. To further learn the effect of combination of VE-822 and 534 cisplatin on the transcriptional profiling, we performed RNA-seg in KYSE450 535 exposure to combination of VE-822 and cisplatin. DEG analysis identified 1163 genes significantly altered in cells bearing treatment, with 555 genes 536 537 up-regulated and 608 genes down-regulated(Fig S3a,b). These genes were 538 then classified based upon their signaling pathways and biological functions 539 using KEGG analysis(Fig S3c,d) and GO analysis(Fig S3e,f). We found that 540 treatment with the combination of VE-822 and cisplatin caused a wide of 541 pathways changes including Hippo pathway, MAPK pathway, JAK-STAT 542 pathway, PI3K-AKT pathway and platinum resistance pathway, etc. To 543 validate the RNA-seq results, we selected 10 DEGs to examine their 544 expression by RT-PCR. These 10 genes, were enriched into drug resistance 545 related signaling pathways, including p53 pathway, apoptosis, platinum drug 546 resistance, PI3K-Akt signaling pathway[28-31] and JAK-STAT signaling 547 pathway[32]. The expression patterns of selected DEGs in the RNA-seq and 548 RT-PCR were highly similar(Fig S4). It indicated that our RNA-seq results was

reliable, and on the other hand, it implied that the dysregulated signaling pathway may be the key to explore the mechanism underlying the sensitization.

552 Moreover, we demonstrated that the combination of cisplatin and VE-822 553 was effective in vivo in KYSE450 and KYSE70 tumor xenograft models but did 554 not affect mouse body weights, suggesting that ATR inhibition is well tolerated. 555 Multiple in vivo studies have established that ATR inhibitors do not exacerbate 556 the toxic effects of multiple genotoxic agents but still synergize with genotoxic 557 therapies.

558 Given that DDR initiation depends on ATM and ATR pathway activation, 559 the presence of ATM may influence the effects of ATR inhibitors. Interestingly, 560 ATM deficiency was detected in 21.5% of patients with ESCC, which 561 motivated us to hypothesize that using an ATR inhibitor in patients with ATM 562 deficiency will lead to synthetic lethality and that patients with ATM deficiency 563 will benefit more from ATR inhibitor treatment. We obtained ATM-deficient ESCC cells by knocking down ATM expression with the CRISPR method. In 564 565 ATM-deficient KYSE450 and KYSE70 cells, the combination of cisplatin and VE-822 induced cell cycle aberrations. Specifically, more cells accumulated at 566 567 S phase. This was not the case in wild-type KYSE cells. Both cell lines 568 exhibited a greater apoptotic response following treatment with the 569 combination of VE-822 and cisplatin, as demonstrated by the data showing 570 that caspase-3 expression and PARP cleavage were increased in combination 571therapy-treated cells. Similar results were observed in the VE-822-alone group. 572 Thus, ATM deficiency may be a predictive biomarker for tumor responses to 573 ATR inhibitor monotherapy and combination therapies. Additionally, previous 574 preclinical studies have identified a series of tumor-specific alterations that 575 affect sensitivity to ATR inhibition. These include defects in the ATM and p53 576 pathways. However, the usefulness of ATM deficiency as a biomarker has not

been extensively examined in ESCC; thus, additional works regarding this
issue are required.

579 Exposure to cisplatin with ATR inhibitor resulted in an increase in cisplatin-DNA adducts, especially in cells with ATM deficiency. This finding 580 indicates that suppressing ATR-Chk1 signaling with VE-822 enhances 581 582 cisplatin activity by enabling the drug to form DNA adducts. Therefore, VE-822 583 may increase cisplatin-DNA accumulation by hindering DNA damage repair 584 induced by cisplatin-DNA. On the other hand, in the previous study, the cells treated with VE-822 along with cisplatin had decreased expression of 585 586 p-glycoprotein. It inferred that VE-822 inhibited the expression of p-glycoprotein to prevent cisplatin efflux, then increasing its concentration[33]. 587 588 In conclusion, our study revealed that endogenous DDR signaling 589 activation plays a critical role in mediating the cisplatin resistance of ESCC. 590 We determined that the ATR inhibitor VE-822 may be an attractive treatment for ESCC, especially when used in combination with cisplatin, as VE-822 591 induces significant sensitization to cisplatin. Specifically, VE-822 synergizes 592 593 with cisplatin in ATM-deficient models of ESCC. Additional works are warranted to explore the possibility that ATM deficiency can serve as a 594 595 biomarker enabling the prospective identification of patients with ESCC who 596 will benefit most from the combination of ATR inhibition and cisplatin.

597

598 **5. Acknowledgements**

599 This work was supported by Beijing Municipal Administration of Hospitals 600 Incubating Program (PX2018044); National Natural Science Foundation for 601 Young Scholars (Grant 81301748); National High Technology Research and 602 Development Program of China (2015AA020403); and Beijing Municipal 603 Administration of hospitals Clinical Medicine Development of special funding 604 support (ZYLX201509).

605

606 6. Conflicts of Interest

607 No potential conflicts of interest were disclosed.

608

609 **7. Author Contribution**

Conceived and designed the experiments: Keneng Chen, Luyan Shen.
Performed the experiments: Qi Shi, Luyan Shen. Analyzed the data: Luyan
Shen, Qi Shi, Bin Dong. Wrote the paper: Luyan Shen, Qi Shi. Patients care,
cases provision and data collection: Keneng Chen, Wanpu Yan, Liang Dai,
Xiaozheng Kang, Yongbo Yang, Hongchao Xiong, Zhen Liang.

615

616 8. Reference

617 [1] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo,

D.M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide:
 sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136

620 (2015) E359-386.

[2] W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q.
Yu, J. He, Cancer statistics in China, 2015, CA Cancer J Clin, 66 (2016)
115-132.

[3] A.R. Davies, J.A. Gossage, J. Zylstra, F. Mattsson, J. Lagergren, N. Maisey, 624 E.C. Smyth, D. Cunningham, W.H. Allum, R.C. Mason, Tumor stage after 625 626 neoadiuvant chemotherapy determines survival after surgery for 627 adenocarcinoma of the esophagus and esophagogastric junction, J Clin Oncol, 32 (2014) 2983-2990. 628

- 629 [4] Medical Research Council Oesophageal Cancer Working Party, Surgical
- 630 resection with or without preoperative chemotherapy in oesophageal cancer: a
- randomised controlled trial, The Lancet, 359 (2002) 1727-1733.

- 632 [5] P.M. Takahara, A.C. Rosenzweig, C.A. Frederick, S.J. Lippard, Crystal
- 633 structure of double-stranded DNA containing the major adduct of the 634 anticancer drug cisplatin, Nature, 377 (1995) 649-652.
- [6] A.M. Weber, A.J. Ryan, ATM and ATR as therapeutic targets in cancer,
 Pharmacol Ther, 149 (2015) 124-138.
- 637 [7] L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M.
- 638 Castedo, G. Kroemer, Molecular mechanisms of cisplatin resistance,
 639 Oncogene, 31 (2012) 1869-1883.
- [8] J. Jin, H. Fang, F. Yang, W. Ji, N. Guan, Z. Sun, Y. Shi, G. Zhou, X. Guan,
- 641 Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in
 642 Triple-Negative Breast Cancer, Neoplasia, 20 (2018) 478-488.
- [9] S.B. Koh, Y. Wallez, C.R. Dunlop, S. Bernaldo de Quiros Fernandez, T.E.
- 644 Bapiro, F.M. Richards, D.I. Jodrell, Mechanistic distinctions between CHK1
- and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine,
 Cancer Res, (2018) pii: canres.3932.2017.
- [10] A. Desai, Y. Yan, S.L. Gerson, Advances in therapeutic targeting of the
- DNA damage response in cancer, DNA Repair (Amst), 66-67 (2018) 24-29.
- [11] L.C. Villaruz, H. Jones, S. Dacic, S. Abberbock, B.F. Kurland, L.P. Stabile,
- 50 J.M. Siegfried, T.P. Conrads, N.R. Smith, M.J. O'Connor, A.J. Pierce, C.J.
- Bakkenist, ATM protein is deficient in over 40% of lung adenocarcinomas,
- 652 **Oncotarget**, (2016) 57714-57725.
- [12] F. Bullrich, D. Rasio, S. Kitada, P. Starostik, T. Kipps, M. Keating, M.
- Albitar, J.C. Reed, C.M. Croce, ATM mutations in B-cell chronic lymphocytic
- 655 leukemia, Cancer Res, 59 (1999) 24-27.
- [13] H. Kim, B. Saka, S. Knight, M. Borges, E. Childs, A. Klein, C. Wolfgang, J.
- 657 Herman, V.N. Adsay, R.H. Hruban, M. Goggins, Having pancreatic cancer with
- tumoral loss of ATM and normal TP53 protein expression is associated with a
- 659 poorer prognosis, Clin Cancer Res, 20 (2014) 1865-1872.

- 660 [14] K.G. Wiman, Restoration of wild-type p53 function in human tumors:
- strategies for efficient cancer therapy, Adv Cancer Res, 97 (2007) 321-338.
- [15] P.M. Reaper, M.R. Griffiths, J.M. Long, J.D. Charrier, S. Maccormick, P.A.
- 663 Charlton, J.M. Golec, J.R. Pollard, Selective killing of ATM- or p53-deficient
- cancer cells through inhibition of ATR, Nat Chem Biol, 7 (2011) 428-430.
- [16] A. Schmitt, G. Knittel, D. Welcker, T.P. Yang, J. George, M. Nowak, U.
- Leeser, R. Buttner, S. Perner, M. Peifer, H.C. Reinhardt, ATM Deficiency Is
 Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung
 Adenocarcinoma, Cancer Res, 77 (2017) 3040-3056.
- [17] A. Min, S.A. Im, H. Jang, S. Kim, M. Lee, D.K. Kim, Y. Yang, H.J. Kim, K.H.
 Lee, J.W. Kim, T.Y. Kim, D.Y. Oh, J. Brown, A. Lau, O.C. MJ, Y.J. Bang,
 AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with
 ATM-deficiency in gastric cancer cells, Mol Cancer Ther, 16 (2017) 566-577.
- [18] Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann
 E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen
 P, Stankovic T, ATR inhibition induces synthetic lethality and overcomes
 chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia
 cells, Blood, 127 (2016) 583-595.
- 678 [19] G. Manic, M. Signore, A. Sistigu, G. Russo, F. Corradi, S. Siteni, M. Musella, S. Vitale, M.L. De Angelis, M. Pallocca, C.A. Amoreo, F. Sperati, S. 679 680 Di Franco, S. Barresi, E. Policicchio, G. De Luca, F. De Nicola, M. Mottolese, A. Zeuner, M. Fanciulli, G. Stassi, M. Maugeri-Sacca, M. Baiocchi, M. Tartaglia, I. 681 682 Vitale, R. De Maria. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells, 683 684 Gut, 67 (2018) 903-917.
- [20] H.J. Kim, A. Min, S.A. Im, H. Jang, K.H. Lee, A. Lau, M. Lee, S. Kim, Y.
 Yang, J. Kim, T.Y. Kim, D.Y. Oh, J. Brown, M.J. O'Connor, Y.J. Bang,

- 687 Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast 688 cancer cells, Int J Cancer, 140 (2017) 109-119.
- [21] L.M. Karnitz, L. Zou, Molecular Pathways: Targeting ATR in Cancer
 Therapy, Clin Cancer Res, 21 (2015) 4780-4785.
- [22] E. Fokas, R. Prevo, E.M. Hammond, T.B. Brunner, W.G. McKenna, R.J.
- 692 Muschel, Targeting ATR in DNA damage response and cancer therapeutics,
- 693 Cancer Treat Rev, 40 (2014) 109-117.
- [23] L.R. Chirieac, S.G. Swisher, J.A. Ajani, R.R. Komaki, A.M. Correa, J.S.
- 695 Morris, J.A. Roth, A. Rashid, S.R. Hamilton, T.T. Wu, Posttherapy pathologic
- stage predicts survival in patients with esophageal carcinoma receiving
 preoperative chemoradiation, Cancer, 103 (2005) 1347-1355.
- [24] T.C. Chou, Drug combination studies and their synergy quantification
 using the Chou-Talalay method, Cancer Res, 70 (2010) 440-446.
- [25] L. Chen, L. Fu, X. Kong, J. Xu, Z. Wang, X. Ma, Y. Akiyama, Y. Chen, J.
 Fang, Jumonji domain-containing protein 2B silencing induces DNA damage
- response via STAT3 pathway in colorectal cancer, Br J Cancer, 110 (2014)
 1014-1026.
- [26] S. Koganti, J. Hui-Yuen, S. McAllister, B. Gardner, F. Grasser, U.
 Palendira, S.G. Tangye, A.F. Freeman, S. Bhaduri-McIntosh, STAT3 interrupts
 ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation, Proc Natl
 Acad Sci U S A, 111 (2014) 4946-4951.
- [27] W.W. Deng, Q. Hu, Z.R. Liu, Q.H. Chen, W.X. Wang, H.G. Zhang, Q.
 Zhang, Y.L. Huang, X.K. Zhang, KDM4B promotes DNA damage response via
 STAT3 signaling and is a target of CREB in colorectal cancer cells, Mol Cell
 Biochem, (2018).
- [28] B. Liu, C. Wang, P. Chen, B. Cheng, Y. Cheng, RACKI induces
 chemotherapy resistance in esophageal carcinoma by upregulating the

PI3K/AKT pathway and Bcl-2 expression, Onco Targets Ther, 11 (2018)211-220.

[29] Z. Amini-Farsani, M.H. Sangtarash, M. Shamsara, H. Teimori,
MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by
targeting PTEN/PI3K/AKT signaling pathway, Cytotechnology, 70 (2018)
203-213.

[30] Y. Ma, G. Zhou, M. Li, D. Hu, L. Zhang, P. Liu, K. Lin, Long noncoding
RNA DANCR mediates cisplatin resistance in glioma cells via activating
AXL/PI3K/Akt/NF-kappaB signaling pathway, Neurochem Int, (2018) pii:
S0197-0186(18)30024-X.

[31] S.C. Tripathi, J.F. Fahrmann, M. Celiktas, M. Aguilar, K.D. Marini, M.K.

Jolly, H. Katayama, H. Wang, E.N. Murage, J.B. Dennison, D.N. Watkins, H.
Levine, E.J. Ostrin, A. Taguchi, S.M. Hanash, MCAM Mediates
Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2
Signaling Pathway, Cancer Res, 77 (2017) 4414-4425.

[32] A.S. Nascimento, L.L. Peres, A.V.S. Fari, R. Milani, R.A. Silva, C.J. da
Costa Fernandes, M.P. Peppelenbosch, C.V. Ferreira-Halder, W.F. Zambuzzi,
Phosphoproteome profiling reveals critical role of JAK-STAT signaling in
maintaining chemoresistance in breast cancer, Oncotarget, 8 (2017)
114756-114768.

[33] C.C. Li, J.C. Yang, M.C. Lu, C.L. Lee, C.Y. Peng, W.Y. Hsu, Y.H. Dai, F.R.
Chang, D.Y. Zhang, W.J. Wu, Y.C. Wu, ATR-Chk1 signaling inhibition as a
therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder
cancer, Oncotarget, 7 (2016) 1947-1959.

738

Figure 1. ATM deficiency occurred in ESCC and p-ATR(Ser428) expression was significantly associated with the overall survival of patients underwent neoadjuvant chemotherapy.

(a). ATM-positive and ATM-negative case.

(b). p-ATR(Ser428) expression pattern by the intensity of positive tumor cells.

0, Negative; grade 1, weak; grade 2, moderate; grade 3, strong.

(c). The association between p-ATR expression and the survival of patients with ESCC underwent neoadjuvant chemotherapy. The Kaplan-Meier survival curve showed that the median survival time (MST) of patients with p-ATR positive expression was significantly shorter than that of patients with negative expression; in the further analysis, with the increase of positive expression cell proportion, the MST of patients was extending; when the p-ATR expression pattern was classified into high expression group and low expression group according to the proportion of positive cells, the MST of high group was significantly shorter than that of low group.

Figure 2. VE-822 inhibited cell growth, induced cell cycle arrest and cell apoptosis in ESCC cells.

(a). The basal level of ATM-CHK2 and ATR-CHK1 activation examined using Western Blotting in a panel of ESCC cell lines, including KYSE70, KYSE150, KYSE450, and KYSE510, which indicated that baseline ATM-CHK2 and ATR-CHK1 activation was essential for cell survival. The densitometry quantification was presented in Fig S2.

(b). KYSE70, KYSE150, KYSE450 and KYSE510 were seed in 96-well plate, and then treated for 48h with gradually increasing concentration of VE-822. The cell viability was assessed using CCK8 staining. Results was presented as the mean percentage of viable cells (Mean±SD), averaged from 3 independent experiments, each with 4 replicates per condition.

(c). The p-ATR and p-CHK1 expression were inhibited and DNA damage accumulation was induced by treatment with VE-822 in a dose-dependent manner as measured by Western Blotting.

(d). VE-822 treatment inhibited STAT3-AKT pathway activation in both KYSE70 and KYSE450.

(e). The effect of VE-822 on cell cycle progression was assessed by flow cytometry using PI/RNase staining. Exactly, VE-822 treatment for 24h significantly increased the proportion of cells in G1 phase, decreased proportion of G2 phase in KYSE70 and KYSE450.

(f). Several cell cycle and apoptosis markers were analyzed using Western Blotting. VE-822 treatment significantly augmented the DNA damage presented by γ -H2AX; VE-822 treatment down-regulated p21 expression for cells to pass the G1/S checkpoint and progress into G2 phase and up-regulated the expression of caspase-3.

(g). VE-822 affected the cancer cell apoptosis. To further investigate whether VE-822 affect cellular apoptosis, cells was stained by Annexin V/PE and underwent flow cytometry analysis after incubated with VE-822 for 8h. The apoptosis rate for VE-822-treated cells was significantly higher than control

Figure 3. VE-822 sensitizes ESCC cells to cisplatin and synergies strongly with cisplatin in ATM-deficient cells.

(a). CI value was calculated according to the Chou-Talalay median effect principle. We observed shift in cisplatin sensitivity in either KYSE450 or KYSE70 cell line. The CI value \leq 0.9 stands for the synergistic effect.

(b). Western Blotting analysis confirmed that ATM expression was knocked out well both in KYSE450 and KYSE70.

(c). Cells were treated with select doses of VE-822 (as indicated) for 48 hours and viability was assessed using CCK8 assay. In the ATM-deficient cells, the IC50 of VE-822 was smaller than control cells, especially for relatively insensitive cell line KYSE70.

(d). There was more significant synergistic effect in ATM-deficient cells than control cells for both of KYSE450 and KYSE70 as presented by lower CI value.

(e). VE-822 potentiated cisplatin efficacy in ESCC xenografts, and the combination causes rapid regression. Nude mice bearing KYSE70 or KYSE450 or ATM-deficient KYSE70 or ATM-deficient KYSE450 were treated with 5mg/kg cisplatin on days1, 4, 7, 10 via intravenous injection or 60 mg/kg VE-822 on days 1, 3, 5 via oral gavage or combination of these two reagents. Tumor growth curves indicated that combination of VE-822 and cisplatin slowed down the tumor growth significantly compared to the single drug, especially for relative insensitive KYSE70.

(f). Although combination of two drugs, the mice did not suffer more weight loss than those in single drug group. In the ATM-deficient xenografts, the gap the weight loss curve between combination group and single group was narrower.

(g). The inhibition of p-CHK1, p-AKT activation were more obvious in ATM-deficiency cells and cleaved PARP was increased as measured by Western Blotting.

Figure 4. In the ATM-deficient cells, VE-822 alone or combination with cisplatin induced more severe DNA damage and cell apoptosis than control cell, as well as induced cell cycle arrest.

(a). Cells were treated with indicated concentration of VE-822, cisplatin, or combination of VE-822 and cisplatin for 24h and underwent flow cytometry analysis by staining with PI/RNase staining for assess the cell cycle progression. Cell cycle was arrested in phase S for ATM-deficient cells by VE-822 treatment.

(b). Cells were treated with indicated concentration of VE-822(2μ M), cisplatin(2μ g/ml), or combination of VE-822(2μ M) and cisplatin(2μ g/ml) for 8h, and then underwent flow cytometry analysis by staining with Annexin V/PE. we observed dramatic cell apoptosis in ATM-deficient cells either with VE-822 or combination treatment.

(c). Expression of several markers which reflects the cell proliferation or cell apoptosis or cell cycle progression or DNA damage was examined using western blotting. Caspase-3 and cleaved-PARP expression remarkably increased in cells exposure to combination of VE-822 and cisplatin. In the ATM-deficient cell, VE-822 combination with cisplatin more dramatic changes in the expression of p-AKT, p21, and γ -H2AX than control cells.

Figure 5. Combination treatment enhanced the DNA damage effect presented by examining fluorescence intensity of γ -H2A.X and p53 in ESCC cells.

Cells treated with cisplatin, VE-822, or combination of two drugs for 24 h were fixed and co-labeled with anti- γ H2AX and anti-p53 antibodies. The γ -H2A.X and p53 foci were analyzed by immunofluorescence microscopy. combination treatment resulted in accumulation of DNA damage presented by stronger and more fluorescence staining of γ -H2AX and p53 (a,b). The enhancement of the DNA damage effect was stronger in ATM-deficiency cells (c,d).

Figure 6. Combination of VE-822 and cisplatin increased cisplatin-DNA accumulation. (a) Cells were treated with cisplatin, VE-822, or combination of two drugs for 24 h. Anti-cisplatin modified DNA antibody was used to specifically bind to Cisplatin-DNA, and the positive signal was examined by using flow cytometry. The combination of VE-822 and cisplatin induced augmentation of cisplatin-DNA adduct.


(b) The percentage of cisplatin modified DNA positive cells were measured by flow cytometry and are represented as mean \pm SD of three replications.


\			, , , , , , , , , ,	- /
		Median survival	5-у	
Item	No. (%)	time, months	survival rate	P value
		(95%CI)	(%)	
Negative VS				0.0152
Positive				010101
ATR-pSer428		94(66 102)	62.2	
non-expression	28(25.6)	6) 84(66-102)	02.2	\sim
ATR-pSer428	82(74.5)	CO(47,74)	47.4	
expression		60(47-74)	17.1	
Expression				0.0005
Grades				0.0335
ATR-pSer428				
non-expression	28(25.5)	84(66-102)	62.2	
ATR-pSer428				
expression	19(17.2)	65(42-88)	42.6	
Grade1			7	
ATR-pSer428				
expression	36(32.7)	48(35-60)	34.2	
Grade2				
ATR-pSer428				
expression	27(24.5)	49(28-70)	30.1	
Grade3				
Low vs. High	X			0.0109
ATR-pSer428		70/00 04)	F 4 7	
low expression	47(42.7)	76(62-91)	54.7	
ATR-pSer428			30.2	
high expression	63(57.3)	53(38-69)		


Table 1. Association between ATR-pSer428 expression and Median survival time(months)/5-y survival rate in the study cohort (n=110)


	cohort (n=11	0)	
ltem	No. (%)		Dualua
Item	TRG1	TRG2/3/4	P value
ATR-pSer428			<0.001
expression			<0.001
non-expression	10(83.3)	18(18.4)	À
expression	2(16.7)	80(81.6)	
ATR-pSer428			
expression			<0.001
expression			
low expression	11(91.7)	36(36.7)	
high expression	1(8.3)	62(63.3)	

Table 2. Association between ATR-pSer428 expression and TRG in the study cohort (n-110)











~





Highlights:

- ATR activation was associated with efficiency of neoadjuvant chemotherapy.
- VE-822 promoted cell apoptosis and induced cell cycle arrest in ESCC cells.
- VE-822 sensitized ESCC cells to cisplatin, in vitro and in vivo.
- VE-822 along with cisplatin induces DNA-cisplatin adduct accumulation.

Chilling Marine